Common use of NOTIFICATIONS AND SUBMISSION OF REPORTS Clause in Contracts

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxxxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & VP, Corporate Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx 0000 Xxxxxxxxx Xxxxxx XxxxxxxxxxxxAshland, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 KY 41101 (000) 000-0000 (office) (000) 000-0000 (fax) Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK KDMC may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxxx Xxxxxx XxxxxxxxxxxxRehab Medical 0000 Xxxxxxxxxxx Xxxxx Indianapolis, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 IN 46250 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Rehab may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 U.S. Compliance Officer AstraZeneca Pharmaceuticals LP 0000 Xxxxxxx Xxxx XX Xxx 00000 Xxxxxxxxxx, XX 00000-0000 Telephone: 000.000.0000 Facsimile: 302.885.9093 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK AstraZeneca may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxx Xxxxxxx 0000-X Xxxxxxxxx Xxxxx Hanover, XX 00000 MD 21076 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Email: Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK a Provider may be required to provide OIG with an electronic copy of each Alliance/Active/Xxxxx/Xxxx/Xxxxxx Corporate Integrity Agreement notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Xxxxxxxx Xxxxxxxxx, MBA, CHC, CHPC Dignity Health 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxx Xxxx Xxxxxx, 0xx xxxxx Xxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 818.409.5266 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Dignity Health may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Xxxxxxxxx Xxxxxx Xxxx Compliance Officer 000 Xxxx Xxxx Xxxxxxxxx Xxxxxxxxx, XX 00000 Telephone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK the Friendship Entities may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & 000.000.0000 First Call: Xxxx Xxxxxx Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxxxxxxxxxxx0000 Xxx Xxxx Xxxxx Xxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK First Call may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 CareMed: CareMed Attention: Compliance Officer 0000 Xxxxxx Xxx Xxxxx 000 Xxxx Xxxxxxx, XX 00000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK CareMed may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Orthofix International, N.V. Senior Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxxxxxxxxxxx0000 Xxxxx Xxxxxxx Lewisville, XX 00000 TelephoneTX 75056 Office: 000.000.0000 214.937.2776 Facsimile: 215.751.7547 214.937.3014 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Orthofix may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective DateDate of this CIA, all notifications and reports required under this CIA shall be submitted to the following entities: Civil Recoveries Branch - Compliance Unit Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 TelephonePhone 000.000.0000 Fax 000.000.0000 Xxxxx Xxxxxx Corporate Compliance Officer Allina Health System 0000 Xxxx Xxxx Xxxx Xxxxxxxxxx, XX 00000 Mailing Address: X.X. Xxx 0000 Xxxxxxxxxxx, XX 00000 Phone 000.000.0000 Facsimile: 215.751.7547 Fax 000.000.0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, delivery or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Xxxx Xxxxx Hospice of the Comforter Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxx Xxxxxxx Altamonte Springs, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 Florida 32714 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK HOTC may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. ‌ Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG:‌ Administrative and Civil Remedies Branch Office of Counsel to the Inspector General, Office of Inspector General‌ U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxKRHS: Kalispell, XX 00000 TelephoneMT 59901 xxxxxxx@xxxx.xxx P: 000.000.0000 Facsimile: 215.751.7547 406.752.1724 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK KRHS may be required to provide OIG with an electronic additional copy of each notification or report required by this CIA CIA, in searchable portable document OIG’s requested format (pdfelectronic or paper), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 511 S. Duck Stillwater, OK 74074 Telephone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Ocean Dental may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Executive Vice President and Compliance Officer Diagnostic Imaging Group, LLC 000 Xxxxx Xxxxxxxx Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 516.977.1451 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK the DIG Entities may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Chief Compliance Officer 0 XXX Xxxxx Xxxxxxxxxx, Xxxxx Xxxxxx 00000 Telephone: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK CVS Health may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Tri-County: Tri-County Ambulance 00 Xxxxxxx Xxxxxx Batesville, IN 47006 (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Tri-County may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Xxxxxxxxx Xxxx, Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza & Chief Operating Officer 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxx Xxxxx Fishkill, XX 00000 NY 12524 Telephone: 000.000.0000 Facsimile: 215.751.7547 845.231.5492 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Mid Xxxxxx may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance eTEL-Rx: X'Xxx Xxxxxx Chief Operating Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxeTEL-Rx 00000 Xxxxx Xxxx Eastpointe, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 MI 48021 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK eTEL-Rx may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Pacific Health Corporation 0000 Xxxxxxxx Xxxxxxxxx, Xxxxx 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxx Xxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 213.355.1540 Email: xxxxx@xxxxxxxxxxxxxxxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK PHC may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Xxxxxxxx Laboratories 00 Xxxxxxxx Xxx Xxxxxx, XX 00000 Telephone: (000) 000-0000 E-Mail: xxxxxxxx@xxxxxxxxxxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Xxxxxxxx may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Senior Vice President & and Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxAmgen Inc. Corporate Integrity Agreement Amgen Inc. One Amgen Center Drive MS 38-4-A Thousand Oaks, XX 00000 CA 00000-0000 Telephone: 000.000.0000 Facsimile: 215.751.7547 805.480.9941 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Amgen may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Vice President, Corporate Integrity Xxxxxx Healthcare System 000 X. Xxxxxxxxxx Street Sumter, SC 29150 Telephone: 000.000.0000 Facsimile: 803.774.9524 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Tuomey may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.